Source:http://linkedlifedata.com/resource/pubmed/id/15172478
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2004-6-2
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0195-668X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
997
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15172478-Amiodarone,
pubmed-meshheading:15172478-Anti-Arrhythmia Agents,
pubmed-meshheading:15172478-Atrial Fibrillation,
pubmed-meshheading:15172478-Electric Countershock,
pubmed-meshheading:15172478-Flecainide,
pubmed-meshheading:15172478-Humans,
pubmed-meshheading:15172478-Verapamil
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Cardioversion threshold, IRAF and beyond.
|
| pubmed:publicationType |
Letter,
Comment
|